Peptide Dosage Chart: Studied Doses, Routes and Status for 30 Peptides

This peptide dosage chart lists 30 peptides and the only doses we could verify: the amounts given to people in published human studies, or the doses printed on an approved drug label. For a handful of peptides, such as semaglutide, tesamorelin and bremelanotide, that evidence is solid. For many of the most talked-about ones, including TB-500, MOTS-c, KPV and CJC-1295 without DAC, no human dosing data exist at all, and the chart says so instead of filling the gap with forum numbers.

Each row also shows the route used in the research, the schedule studied, who was studied and where it stands with regulators as of October 2026. The previous version of this page mixed trial doses with Reddit figures and seller listings. Those numbers have been removed.

The Peptide Dosage Chart

How doses are labeled in this chart. Every number in the “Studied dose” column comes from either a published human study or an approved drug label, linked in the Source column. Where we could not find either, the cell reads “No human dosing data” and no number is given. We do not list doses reported online, by sellers or by clinics, even as a reference point.

Abbreviations and status terms:

• SC is subcutaneous (under the skin), IV is intravenous and PK is pharmacokinetic.
• Cat. 2 means the substance is on the FDA’s Category 2 list of bulk drug substances that may present significant safety risks in compounding. The list labels each entry 503A or 503B, the two types of compounding pharmacy.
• Former Cat. 2 means the FDA moved the substance off the list after the people who nominated it withdrew their nominations. That does not make it legal to compound.
• Removed from Cat. 2, Apr 2026 refers to the 12 peptides the FDA announced it would remove on April 15, 2026, ahead of advisory committee review.
• PCAC is the FDA’s Pharmacy Compounding Advisory Committee. Vote counts are from its July 23–24, 2026 meeting. A “backed” vote recommends adding the peptide to the list compounders may use. It is advisory, and the FDA has not issued a final decision.

How to Read This Peptide Dosage Chart

A peptide dosage chart is only useful if you know what each number does and does not tell you.

“Studied dose” is a fact about a study, not a target. It is the amount a research team gave a specific group of people under medical supervision. Some of those doses were picked to find the most a person could tolerate. Others, like the 100 mcg GHRP-2 dose, were tested for five days to see whether the body stopped responding. A studied dose is not proof that the dose works, or that it is safe outside that setting.

“Studied in” matters as much as the number. Sermorelin’s 30 mcg/kg dose comes from GH-deficient children. Tesamorelin’s 2 mg dose comes from adults with HIV and abdominal fat. Ipamorelin’s only multi-day human trial was in patients recovering from bowel surgery, and it did not beat placebo on its main goal. None of those groups looks like a healthy lifter.

Approved labels are different from trials. For the five peptides with a current FDA label, the dose comes from that label and the trials behind it. A label dose is set for one approved use. Using the same drug for something else, or getting it from a compounder or a “research” seller, is outside what the label covers.

“No human dosing data” means exactly that. For these peptides, any dose you see online came from animal studies, seller guides or user reports. The FDA’s own reviews said it found no human exposure data for TB-500 or MOTS-c by any route, and no human studies of KPV. A 2026 review in Frontiers in Endocrinology found no peer-reviewed human studies of CJC-1295 without DAC, PEG-MGF or IGF-1 LR3.

What Changed From the Old Chart

The previous version of this page listed about 40 peptides. Several doses had no source, and some were far off. Kisspeptin-10 was listed at “5–10 mg/day” by IV, while the only human dose-response study used IV boluses of 0.01–3 mcg/kg. The old chart also gave “typical cycle lengths” and timing advice based on user reviews. Those columns have been removed because no trial tested a bodybuilding-style “cycle” for these peptides.

Peptide Dosage Units: mcg, mg, IU and mcg/kg

Most peptide dosing errors come from units, not from the peptide itself.

• 1 mg (milligram) is 1,000 mcg (micrograms). Semaglutide and tirzepatide are dosed in mg. Most growth hormone secretagogues in this chart were studied in mcg.
• mcg/kg or mg/kg means the dose was scaled to body weight. In the Wessells melanotan II study, men received 0.025 mg/kg. For an 80 kg participant, that works out to 2 mg. A weight-based study dose cannot be compared with a flat dose until you do that math.
• nmol/kg (nanomoles per kilogram) appears in older studies such as the DSIP trial. It counts molecules rather than weight, so converting it to mcg depends on the peptide’s molecular weight.
• IU (international units) is used for products like HGH and HCG, not for the peptides in this chart. IU cannot be swapped for mg or mcg without a conversion factor specific to that substance.
• Concentration (mg/mL) describes a solution, not a dose. LL-37 was tested as a 0.5–3.2 mg/mL solution spread on a wound, which is not the same as a 0.5 mg injection.

For turning a vial strength and a water volume into syringe units, use our peptide dosage calculator. It does the arithmetic only and does not suggest a dose. Our guide on how to reconstitute peptides covers the mixing steps.

SwissChems Contents6 sections01What Is SwissChems?02Product Range03Top 3 Featured Products04Why It Gets Attention From Fitness Researchers05Testing, Documentation & Regulatory History06Frequently Asked Questions SwissChems is an online research-compound supplier covering SARMs,…

9.2Excellent

Visit SwissChemsBRAWN1010% OFFCopy

Pros

• Exceptional purity & testing (≥98%)
• Pharmaceutical-style packaging for stability
• Broad catalog across peptides & nootropics
• Strong reputation & consistency across years

Cons

• Some items frequently out of stock due to high demand
• Limited long-term data for some compounds

Route and Timing: What the Research Actually Used

The old page had columns for “injection site” and “timing of dose.” Here is what the studies and labels actually say.

Route Changes the Dose

Many studied peptide doses were given by IV, often as a single infusion in a clinic. The BPC-157 human pilot, the ipamorelin trial, the kisspeptin-10 study and the GHRP-6 study all used IV dosing. An IV dose reaches the bloodstream at once. A subcutaneous injection is absorbed more slowly and sometimes less completely, so an IV dose cannot simply be repeated under the skin.

Hexarelin is a clear example. In a 1994 study, the same team gave it by IV, under the skin, through the nose and by mouth. Bioavailability was about 77% under the skin, 4.8% through the nose and 0.3% by mouth, which is why the oral doses tested were in milligrams rather than micrograms.

Where Labels Specify Injection Sites

The FDA labels for semaglutide and tirzepatide list the abdomen, thigh or upper arm. Tesamorelin’s label lists the abdomen, with sites rotated. Bremelanotide’s lists the abdomen or thigh. For a general guide to sites and technique, see our pages on peptide injection sites and how to inject peptides.

Where Timing Was Part of the Protocol

Timing appears in only a few protocols. Sermorelin was given at bedtime in the pediatric trial, and a small study in older men used 2 mg nightly for six weeks. Bremelanotide’s label says to inject at least 45 minutes before expected sexual activity. Wegovy’s label says it can be taken at any time of day, with or without meals. For most other peptides, the “before bed” or “fasted” advice found online does not come from a trial.

Peptides With an Approved Label

Five peptides in this chart have a current FDA-approved label, and their doses are the most reliable numbers here.

• Semaglutide (Wegovy) starts at 0.25 mg once weekly and rises every four weeks to a 2.4 mg maintenance dose. In the STEP 1 trial, adults on 2.4 mg lost an average of 14.9% of body weight over 68 weeks, compared with 2.4% on placebo.
• Tirzepatide (Zepbound) starts at 2.5 mg weekly, with maintenance doses of 5, 10 or 15 mg. In SURMOUNT-1, weight loss at 72 weeks was 15.0%, 19.5% and 20.9% at those three doses.
• Tesamorelin (Egrifta) is labeled at 2 mg once daily. In the pivotal trial, visceral fat fell 15.2% over 26 weeks and rose 5.0% on placebo.
• Bremelanotide (Vyleesi) is labeled at 1.75 mg as needed for premenopausal women with low sexual desire. The label warns of nausea in 40% of patients and a temporary rise in blood pressure.
• Elamipretide (Forzinity), sold online as SS-31, received accelerated approval in 2025 for Barth syndrome at 40 mg once daily.

Retatrutide is not on this list. It is still investigational, and Lilly has tested it at up to 12 mg weekly in phase 3. Our retatrutide report covers where it stands. Sermorelin was approved as Geref in 1997 and later taken off the market. The FDA later found it was not withdrawn for safety or effectiveness reasons.

Peptides With Little or No Human Data

Most peptides people search for sit in a gray zone: small, short studies at best, and often nothing at all.

BPC-157 has three published human reports with 30 people in total, according to a 2026 systematic review. None had a control group, and the review rated the certainty of evidence as very low. The dose in the chart comes from a two-person IV safety pilot. Our BPC-157 profile covers the compound in more detail.

TB-500 is often treated as interchangeable with thymosin beta-4, but it is a short fragment. The full-length protein was given by IV to healthy volunteers at 42–1,260 mg a day for 14 days in a safety study. That says nothing about how much of the fragment, injected under the skin, would do anything. For what the research on the fragment does and does not show, see our TB-500 report.

Growth hormone secretagogues such as GHRP-2, GHRP-6, hexarelin and ipamorelin were mostly studied as single doses to measure a growth hormone spike. In one study of GHRP-2 given daily for five days, the GH response weakened day by day, and IGF-1 did not rise.

Epitalon, MOTS-c, KPV, IGF-1 LR3 and CJC-1295 without DAC have no human dosing data that we, or the FDA reviewers, could find.

What About Peptide Stacks?

The old version of this page listed eight “peptide stacks” with doses for each. None of those combinations has been tested as a combination in a controlled human trial that we could find. The closest is a retrospective chart review in which four patients received knee injections of BPC-157 combined with thymosin beta-4. It had no control group and no standard way of measuring results.

Stacking two peptides that work on the same system, such as a GHRH analog with a GH secretagogue, does not have a known studied dose. The section has been removed rather than replaced.

Regulatory Status of These Peptides

Several peptides in this chart changed regulatory status in 2026.

In April 2026, the FDA announced it would remove 12 peptides, including BPC-157, TB-500, GHK-Cu and melanotan II, from its Category 2 list. In July 2026, its advisory committee voted to recommend six of seven peptides it reviewed for the list compounders may use, including BPC-157, TB-500, KPV, MOTS-c, epitalon and semax. It voted against DSIP. FDA staff had recommended against all seven.

None of that makes these peptides FDA-approved drugs. The votes are advisory, the FDA has not finalized any change, and peptides sold as “research chemicals” are still unapproved products. Ipamorelin, GHRP-2, GHRP-6, kisspeptin-10 and ibutamoren (MK-677) remain on Category 2. Laws also differ by country. Our guide to whether peptides are legal covers the country-by-country picture. The statuses in this chart reflect sources available on October 22, 2026, and may change.